Our science
We have 30 years’ experience in translating research into new drugs and diagnostics.
Our capabilities and expertise ensure seamless progress for your research, with a strong commitment to preserving your IP. We also offer tailored strategic advice and can connect you with commercial and not-for-profit partners and patient groups.
Our scientific capabilities
Therapeutics
Over 30 years’ experience in antibody humanisation, alongside expert capabilities in antibody discovery and small molecule drug discovery.
Diagnostic development
We support proof of concept through design and development, including clinical studies at our labs in Edinburgh is certified to ISO 13485.
Supporting functions and technologies
We develop and provide technologies and functions that support innovative science.
Induced pluripotent stem cell (iPSC) technology*
Our gold-standard iPSC models for neurodegeneration are essential for effective mode of action (MOA), target validation and drug discovery projects.
Microbiology
Our established facilitates and technologies can support the study of mode of action (MOA), antibiotic resistance and drug screening.
Data science*
Our long-established technologies include methods to understand structure-activity relationships or use protein structures to design new molecules. We’re expanding into new areas, including AI and machine learning.
* capability or platform in development
Other ways we can support your science
We partner with academics, early-stage biotechs, charities, healthcare professionals and industry.
Funding
Early ventures investment
IP protection and
tech transfer
Some of our partnerships
-
Drug repurposing call to treat chronic respiratory infection
Drug repurposing call to treat chronic respiratory infection LifeArc has committed £10m to fund up to five consortia programmes that seek to develop therapeutics…
-
ReACT Africa
Tackling drug-resistant infections with ReACT Africa In partnership with ReAct (Action on Antibiotic Resistance) Africa, we have launched ASPIRE, a project aimed at tackling…
Latest news
-
LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases
Read more: LifeArc launches £40m research centres that will unlock new tests, treatments and cures for people living with rare diseases -
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya